myasthenia gravis
Conditions
Interventions
Standard dose group:Rituximab 400mg, once a week for 4 weeks
Low dose group:100mg, once a week, for 4 consecutive weeks or 100mg + 500mg single treatment
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with myasthenia gravis who have been treated with rituximab.
Exclusion criteria
Exclusion criteria: 1. Aged 80 years; 2. Patients who may have serious complications after rituximab treatment, such as infection, cardiac insufficiency, severe blood diseases, etc.; 3. Plasma replacement was used in the last 3 months; 4. Pregnant and lactating patients and patients planning to give birth during the trial; 5. Patients with malignant tumors of various systems (except thymoma); 6. The patient has a mental illness or state that does not understand the nature, scope and possible consequences of the study; 7. Drug abuse or alcoholism; 8. Patients who do not want to sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters;Effective rate;Cost effectiveness ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Concentration of rituximab;Myasthenia gravis clinical score;Percentage of lymphocytes; | — |
Countries
China
Contacts
Public ContactChen Di
Beijing Hospital
Outcome results
None listed